SanguiBioTech GmbH And German Pharmaceutical Company Plan Joint Development Of Haemoglobin Wound Spray
10/19/2005 5:08:47 PM
A renowned German medium sized pharmaceutical company and SanguiBioTech GmbH of Witten, Germany, a wholly owned subsidiary of Sangui BioTech International, Inc. (NASD OTCBB: SGBI), have declared their intention to jointly develop a haemoglobin wound spray based on Sangui's artificial oxygen carrier for the treatment of chronic wounds. The product has undergone a number of initial clinical experiments which give rise to the expectation that the new product may revolutionize the treatment of chronic wounds.
comments powered by